Aluminium Bone Deposits in Normal Renal Function Patients after Long-Term Treatment by Plasma Exchange

1989 ◽  
Vol 12 (10) ◽  
pp. 664-667 ◽  
Author(s):  
C. Mousson ◽  
S.A. Charhon ◽  
M. Ammar ◽  
M. Accominotti ◽  
G. Rifle
Keyword(s):  
Renal Function ◽  
Bone Formation ◽  
Plasma Exchange ◽  
Normal Renal Function ◽  
Bone Biopsy ◽  
Term Treatment ◽  
Normal Range ◽  
Non Invasive ◽  
Long Term Treatment

The accumulation of aluminium (AI) can cause AI bone deposits, osteomalacia and encephalopathy. As albumin solutions used as replacement fluid in plasma exchange (PE) are contaminated with AI, we studied AI overload in two symptomless patients with normal renal function, treated by long-term plasma exchange (PE). Total AI loading was calculated at 1750 μmol in patient 1 (178 PE sessions) and 2100 μmol in patient 2 (153 PE sessions). Bone biopsy showed AI deposits and low bone formation without osteomalacia in patient 1 and only osteoporosis in patient 2. Plasma AI levels were useless in detecting early AI overload, because the remained in the normal range, even after PE in both patients. Bone biopsy was the best means of recognizing AI intoxication, but cannot be recommended for frequent evaluations. However, the desferrioxamine mobilization test can be proposed as a repetitive non-invasive investigation method.

scholarly journals Long-Term Therapeutic Plasma Exchange to Prevent End-Stage Kidney Disease in Adult Severe Resistant Henoch-Schonlein Purpura Nephritis

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
Patrick Hamilton ◽  
Olumide Ogundare ◽  
Ammar Raza ◽  
Arvind Ponnusamy ◽  
Julie Gorton ◽  
...  
Keyword(s):  
Renal Function ◽  
Kidney Disease ◽  
Plasma Exchange ◽  
Kidney Injury ◽  
Term Treatment ◽  
Therapeutic Plasma Exchange ◽  
End Stage Kidney Disease ◽  
Long Term Treatment ◽  
End Stage

A 27-year-old man presented with a palpable purpuric skin rash and joint and abdominal pain in April 2010. He had acute kidney injury and his creatinine quickly deteriorated to 687 μmol/L, with associated nephrotic range proteinuria. Kidney biopsy showed crescentic Henoch-Schonlein nephritis. He was treated with intravenous cyclophosphamide and prednisolone despite which his renal function deteriorated; he required haemodialysis for a short duration and seven sessions of therapeutic plasma exchange (TPE). Renal function improved, but after discharge from hospital he suffered 2 further relapses, each with AKI, in 4 months. Cyclophosphamide was not effective and therefore Rituximab was introduced. He initially had a partial response but his renal function deteriorated despite continued therapy. TPE was the only treatment that prevented rapid renal functional deterioration. A novel long-term treatment strategy involving regular TPE every one to two weeks was initiated. This helped to slow his progression to end-stage kidney disease over a 3-year period and to prolong the need for renal replacement therapy over this time.

Long-Term Treatment with Pivmecillinam in Patients with Recurrent Bacteriuria

1982 ◽  
Vol 10 (3) ◽  
pp. 179-182
Author(s):  
B Bresky ◽  
K Lincoln
Keyword(s):  
Escherichia Coli ◽  
Adverse Effect ◽  
Renal Function ◽  
Term Treatment ◽  
The Body ◽  
End Of Treatment ◽  
Long Term Treatment ◽  
Tract Infections

Thirty out-patients with chronic recurrent urinary tract infections, who had failed to respond to 10 days treatment with either pivmecillinam and/or amoxycillin, received a 3-month course of pivmecillinam at a dose of 200 mg, three times daily. Twenty-seven patients had bacteriuria due to Enterobacteriaceae, mainly Escherichia coli, sensitive to mecillinam in vitro. Pivmecillinam eradicated all the initial urinary pathogens. Reinfections occurred during treatment in three patients, who remained asymptomatic. Four subjects complained of gastro-intestinal side-effects, and therapy was withdrawn in three instances. Another three patients described unusual adverse events towards the end of the course of treatment, described as an odd sensation in the body and a desire for salt. The sensation disappeared a few days after the end of treatment. Treatment with pivmecillinam had no adverse effect on haematopoietic, hepatic or renal function.

Long-term clinical use of mirabegron in patients with overactive bladder syndrome

2020 ◽  
Vol 13 (4) ◽  
pp. 460-464
Author(s):  
Tomasz Wiatr ◽  
Piotr Chłosta
Keyword(s):  
Overactive Bladder ◽  
Term Treatment ◽  
Overactive Bladder Syndrome ◽  
Invasive Treatment ◽  
Treatment Development ◽  
Non Invasive ◽  
Antimuscarinic Drugs ◽  
Adrenoceptor Agonist ◽  
Long Term Treatment

Overactive bladder syndrome (OAB) is defined by the International Continence Society (ICS) as urinary urgency with increased daytime frequency and nocturia in the absence of proven infection or any other pathology, usually with or without urgency incontinence. Pharmacotherapy with antimuscarinic drugs is highly effective, but more than 60% of patients discontinue the treatment. Development of mirabegron, a β3-adrenoceptor agonist (β3-AR), has become an expected pharmacotherapy option for the non-invasive treatment of overactive bladder. The available studies show that long-term treatment with 50 mg mirabegron in patients with OAB is associated with reducing the severity of symptoms. Data from clinical trials show that mirabegron provides efficacy similar to antimuscarinic drugs, but with a better tolerance profile.

Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function

1997 ◽  
Vol 26 (4) ◽  
pp. 816-825 ◽  
Author(s):  
Alberto Malesci ◽  
Milena Tacconi ◽  
Angela Valentini ◽  
Mauro Basilico ◽  
Elettra Lorenzano ◽  
...  
Keyword(s):  
Renal Function ◽  
Portal Hypertension ◽  
Term Treatment ◽  
Long Term Treatment

Fulgazepam: A Fulgimide-Based Potentiator of GABAA Receptors

2019 ◽  
Author(s):  
Karin Rustler ◽  
Galyna Maleeva ◽  
Alexandre M. J. Gomila ◽  
Pau Gorostiza ◽  
Piotr Bregestovski ◽  
...  
Keyword(s):  
Protein Function ◽  
Biological Evaluation ◽  
Term Treatment ◽  
Allosteric Modulators ◽  
Design Synthesis ◽  
Non Invasive ◽  
Long Term Treatment ◽  
Benzodiazepine Derivatives ◽  
Synthesis And Biological Evaluation

The <i>γ</i>-aminobutyric acid gated chloride channel represents the major mediator of inhibitory neurotransmission in the mammalian central nervous system and its dysfunction is related to severe diseases like epilepsy and depression, which can be relieved by the application of allosteric modulators. However, the drugs’ potential side-effects limit their application for long-term treatment. Applying light as external stimulus to modify the pharmacophore’s activity, as emerged in the field of photopharmacology, provides a non-invasive tool with high spatial and temporal resolution for the modulation of protein function. Herein, we report the design, synthesis, and biological evaluation of photochromic fulgimide-based benzodiazepine derivatives as light-controllable potentiators of GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs). A photocontrolled potentiator of GABA<sub>A</sub>Rs (Fulgazepam) has been identified that does not display agonist or antagonist activity and allows manipulating zebrafish larvae swimming.

The effect of nisoldipine on renal function in the long-term treatment of hypertension in patients with and without renal impairment

1989 ◽  
Vol 37 (5) ◽  
pp. 437-441 ◽  
Author(s):  
J. Wilson ◽  
M. M. A. E. Wahbha ◽  
P. G. Martin ◽  
R. Hainsworth ◽  
A. M. Brownjohn ◽  
...  
Keyword(s):  
Renal Function ◽  
Renal Impairment ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Treatment Of Hypertension
Sign in / Sign up

Export Citation Format

Share Document